A phase 2 study of BRC-002
Latest Information Update: 05 Dec 2024
Price :
$35 *
At a glance
- Drugs BRC 002 (Primary)
- Indications Complex regional pain syndromes
- Focus Therapeutic Use
- 05 Dec 2024 New trial record
- 03 Dec 2024 According to a Biopharmaceutical Research Company media release, the company plans to commence enrollment in this trial by the end of 2025 and is currently seeking input from the FDA on the development plan.